Glioblastoma Multiforme, Diagnosis and Treatment; Recent Literature Review
- PMID: 28521700
- DOI: 10.2174/0929867324666170516123206
Glioblastoma Multiforme, Diagnosis and Treatment; Recent Literature Review
Abstract
Background: Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor, with an incidence of 3.19 cases per 100,000 person years and remarkably poor prognosis showing a 5-year survival rate of 4-5%, and only a 26-33% survival rate at 2 years in clinical trials.
Objective: In this paper, we review the different types of treatment modalities based on the relevant databases. Methods of diagnosis will be described briefly.
Method: Systemic compilation of the relevant literature.
Results & conclusion: Today's treatments cannot cure GBM patients but only extend their overall survival. The use of chemoradiation, immunotherapy, and radio sensitizers as an adjuvant therapy cannot reduce the high rates of recurrence within a few months after treatment. Radiotherapy will remain the backbone of the treatment but new treatment modalities must be developed.
Keywords: Biologic agent; chemotherapy; glioblastoma multiforme; immunotherapy; radiation therapy; vaccination..
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
Similar articles
-
Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial.World Neurosurg. 2012 May-Jun;77(5-6):736-44. doi: 10.1016/j.wneu.2011.08.020. Epub 2011 Nov 7. World Neurosurg. 2012. PMID: 22120301 Clinical Trial.
-
Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.J Neurosurg. 2014 Sep;121(3):543-53. doi: 10.3171/2014.5.JNS132392. Epub 2014 Jul 4. J Neurosurg. 2014. PMID: 24995786 Clinical Trial.
-
Immune Phenotype Correlates With Survival in Patients With GBM Treated With Standard Temozolomide-based Therapy and Immunotherapy.Anticancer Res. 2019 Apr;39(4):2043-2051. doi: 10.21873/anticanres.13315. Anticancer Res. 2019. PMID: 30952748 Clinical Trial.
-
Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.Anticancer Res. 2017 Jan;37(1):21-33. doi: 10.21873/anticanres.11285. Anticancer Res. 2017. PMID: 28011470 Review.
-
Management of Glioblastoma Multiforme in Elderly Patients: A Review of the Literature.World Neurosurg. 2017 Sep;105:53-62. doi: 10.1016/j.wneu.2017.04.153. Epub 2017 Apr 30. World Neurosurg. 2017. PMID: 28465276 Review.
Cited by
-
Peimine induces apoptosis of glioblastoma cells through regulation of the PI3K/AKT signaling pathway.Exp Ther Med. 2024 Oct 3;28(6):447. doi: 10.3892/etm.2024.12737. eCollection 2024 Dec. Exp Ther Med. 2024. PMID: 39430343 Free PMC article.
-
Viral Gene Therapy for Glioblastoma Multiforme: A Promising Hope for the Current Dilemma.Front Oncol. 2021 May 13;11:678226. doi: 10.3389/fonc.2021.678226. eCollection 2021. Front Oncol. 2021. PMID: 34055646 Free PMC article. Review.
-
Modulation of Blood-Brain Barrier Permeability by Activating Adenosine A2 Receptors in Oncological Treatment.Biomolecules. 2021 Apr 24;11(5):633. doi: 10.3390/biom11050633. Biomolecules. 2021. PMID: 33923147 Free PMC article. Review.
-
G-protein-coupled receptor GPR17 inhibits glioma development by increasing polycomb repressive complex 1-mediated ROS production.Cell Death Dis. 2021 Jun 12;12(6):610. doi: 10.1038/s41419-021-03897-0. Cell Death Dis. 2021. PMID: 34120140 Free PMC article.
-
Psychosocial factors associated with workability after surgery in cancer survivors: An explorative study.J Health Psychol. 2023 Sep;28(11):999-1010. doi: 10.1177/13591053231151286. Epub 2023 Feb 18. J Health Psychol. 2023. PMID: 36800903 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical